Metabolic HealthFDA Approves First Oral GLP-1 Weight Loss Pill Orforglipron
The FDA has approved Foundayo (orforglipron), the first oral GLP-1 receptor partial agonist for long-term weight management in adults with obesity or overweight with at least one weight-related health condition. Unlike Wegovy (semaglutide) and other GLP-1 drugs that require weekly injections, orforglipron is taken as a daily pill, potentially expanding access and adherence for millions of patients. The approval came approximately 50 days after filing, making it the first new molecular entity approved under the FDA's new National Priority Voucher program. Two phase 3 trials spanning 72 weeks demonstrated significant weight reduction compared to placebo. This milestone could shift how obesity is treated, bringing effective pharmacotherapy to patients who prefer or require a non-injectable option.
